Topic
Personalised Medicine
84 published works
Turtle Talk
NIH to Host Consultations and a Listening Session on All of Us Program, NIH Tribal Data Sovereignty, and NIMHD Resource Center for Tribal Epidemiological Centers Initiative
From the Federal Register announcement: NIH All of Us Research Program Tribal Consultation On Monday, October 19, 2026, from 12:00 p.m. to 2:00 p.m. Pacific Time, NIH will conduct a…
Hall, Render, Killian, Heath & Lyman, P.C. Blog
OIG Issues Favorable Opinion Allowing Precision Oncology Company to Provide Free Supplemental Reports Displaying Multi-Cancer Detection Test Results
By Hall Render
The U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 26-11 (“Advisory Opinion”) on May 20, 2026. This favorable opinion concerns a precision oncology…
RF EMerge
Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update
By Aydin H. Harston, Michael Ellenberger, Stephanie Waltersdorff
Targeted protein degradation (TPD) has moved from promising concept to near-commercial reality in under a decade. By hijacking the cell’s ubiquitin-proteasome system, TPD therapies eliminate disease-driving proteins entirely rather than…
Duane Morris Life Sciences Law
Vicki Norton to Speak at Personalized Cancer Vaccine Summit
By Duane Morris
Duane Morris Partner Vicki G. Norton, Ph.D., will be speaking at the Personalized Cancer Vaccine Summit in Boston on Thursday, November 20. She will be on the panel “Health Economics,…
RF EMerge
Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
By Aydin H. Harston, Michael Ellenberger, Stephanie Waltersdorff
A. Introduction: Harnessing Cellular Machinery for Precision Medicine Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making…
BioSlice Blog
The UK’s MHRA launches consultation on draft guideline on individualised mRNA cancer immunotherapies
By Emma Elliston, Adela Williams
On 3 February 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) launched a consultation asking for stakeholders’ views on draft guideline in relation to the regulation of individualised…
Al-Mirsal
Healthcare and Life Sciences Trends and Developments Across MENA
The healthcare and life sciences ecosystem is witnessing significant growth in the Middle East as the GCC continues to seek economic diversification. By Brian A. Meenagh, Sara Patel, and Lucy…
Big Molecule Watch
UK Authorizes World-First Gene Therapy from Vertex and CRISPR Therapeutics for Blood Disorders
By Yoko Bian
Earlier today, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for their CRISPR/Cas9 gene therapy, CASGEVY (exagamglogene autotemcel), marking the…
Personalized Medicine Bulletin
NIH Funded Research Centers Support Precision Medicine Research
Somatic mosaicisms are post-conception changes to cellular DNA that lead to genetic variation among cells in an organism. These changes can account for variation among individuals’ health or disease progression.…
Personalized Medicine Bulletin
Cancer Moonshot Initiative Adds Precision Surgery Effort
The White House recently announced the Precision Surgery Initiative (PSI) as a “first-of-its kind Advanced Research Projects Agency for Health (ARPA-H) program to develop novel technologies” to more precisely excise…